VERTEX PHARMACEUTICALS INC / MA (VRTX)
Data as of , from SEC Form 4 filings.
See up to 3 months of VRTX. The 7-day demo opens the 1M and 3M ranges and puts VRTX on your watchlist.
Start 7-day demoLatest VRTX insider trades
- Ourania Tatsis - OfficerOpen-market sale$787K
Duncan McKechnie - OfficerOpen-market sale$800K
About VERTEX PHARMACEUTICALS INC / MA (VRTX)
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).
- BOSTON, MA
- 6,400
- 1991
- XNAS
VRTX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 6 | 30,316 | |
| Bona-fide gift | 1 | 6,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
VRTX insider transactions (Form 4)
42122 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 1 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Grunsven Jasper van - Officer | Grant or award | Common Stock | 8,682 footnote F1 | $0.00 | - | |
| ||||||
| Kristen Ambrose - Officer | Grant or award | Common Stock | 5,000 footnote F1 | $0.00 | - | |
| ||||||
| Bruce I. Sachs - Director | Gift | Common Stock | 6,000 | $0.00 | - | |
| Ourania Tatsis - Officer | Grant or award | Common Stock | 8,251 footnote F1 | $0.00 | - | |
| ||||||
 Amit Sachdev - Officer | Grant or award | Common Stock | 8,251 footnote F1 | $0.00 | - | |
| ||||||
| Bruce I. Sachs - Director | Grant or award | Deferred Stock Units | 99.94 | $475.28 | $47K | |
 Alan M. Garber - Director | Grant or award | Deferred Stock Units | 31.56 | $475.28 | $15K | |
| Ourania Tatsis - Officer | Open-market sale | Common Stock | 1,500 | $524.99 | $787K | |
| Duncan McKechnie - Officer | Open-market sale | Common Stock | 1,541 | $519.00 | $800K | |
| Joy Liu - Officer | Open-market sale | Common Stock | 828 | $502.71 | $416K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 596 | $482.50 | $288K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 1,020 | $462.17 | $471K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 4,062 | $450.00 | $1.83M | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 1,745 | $450.00 | $785K | |
| Joy Liu - Officer | Open-market sale | Common Stock | 828 | $439.91 | $364K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 1,974 | $450.00 | $888K | |
| Mark E. Bunnage - Officer | Open-market sale | Common Stock | 33 | $453.45 | $15K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 1,354 | $453.45 | $614K | |
| Carmen Bozic - Officer | Open-market sale | Common Stock | 6,988 | $450.00 | $3.14M | |
 Suketu Upadhyay - Director | Derivative | Common Stock | 796 | - footnote F1 | - | |
| Suketu Upadhyay - Director | Grant or award | Stock Option (Right to Buy) | 2,866 | $0.00 | - | |
| Suketu Upadhyay - Director | Grant or award | Deferred Stock Units | 796 | - footnote F1 | - | |
| ||||||
| Nancy Thornberry - Director | Grant or award | Common Stock | 472 footnote F1 | $0.00 | - | |
| Nancy Thornberry - Director | Derivative | Common Stock | 398 | - footnote F2 | - | |
| Nancy Thornberry - Director | Grant or award | Stock Option (Right to Buy) | 1,433 | $0.00 | - | |
| Nancy Thornberry - Director | Grant or award | Deferred Stock Units | 398 | - footnote F2 | - | |
| ||||||
| Jennifer Schneider - Director | Grant or award | Common Stock | 472 footnote F1 | $0.00 | - | |
| Jennifer Schneider - Director | Derivative | Common Stock | 796 | - footnote F2 | - | |
| Jennifer Schneider - Director | Grant or award | Stock Option (Right to Buy) | 1,433 | $0.00 | - | |
| Jennifer Schneider - Director | Grant or award | Deferred Stock Units | 796 | - footnote F2 | - | |
| ||||||
| Bruce I. Sachs - Director | Grant or award | Stock Option (Right to Buy) | 2,866 | $0.00 | - | |
 Diana McKenzie - Director | Grant or award | Common Stock | 943 footnote F1 | $0.00 | - | |
| Diana McKenzie - Director | Derivative | Common Stock | 796 | - footnote F2 | - | |
| Diana McKenzie - Director | Grant or award | Deferred Stock Units | 796 | - footnote F2 | - | |
| ||||||
| Joy Liu - Officer | Open-market sale | Common Stock | 1,104 | $425.02 | $469K | |
 Michel Lagarde - Director | Grant or award | Stock Option (Right to Buy) | 2,866 | $0.00 | - | |
| Alan M. Garber - Director | Grant or award | Common Stock | 472 footnote F1 | $0.00 | - | |
| Alan M. Garber - Director | Grant or award | Stock Option (Right to Buy) | 1,433 | $0.00 | - | |
| ||||||
| Lloyd Carney - Director | Grant or award | Stock Option (Right to Buy) | 2,866 | $0.00 | - | |
| Sangeeta N. Bhatia - Director | Grant or award | Common Stock | 943 footnote F1 | $0.00 | - | |
| Sangeeta N. Bhatia - Director | Open-market sale | Common Stock | 318 | $423.73 | $135K | |
| ||||||
| Suketu Upadhyay - Director | Grant or award | Deferred Stock Units | 80.51 | $442.50 | $36K | |
Recent VRTX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Bruce I. Sachs | Director | 1,210 | $663K | View on EDGAR | |
| - | - | - | - |
Stock trades in VRTX disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 David J. TaylorRepublican, OH-02 | Sale |
VRTX insider trading FAQ
What is the latest insider trade for VRTX?
VERTEX PHARMACEUTICALS INC / MA (VRTX) had 7 insider filings in the last 90 days, with the most recent on 2026-09-10. The full record for VRTX runs to 122 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying VRTX stock?
No insider purchases of VRTX were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling VRTX stock?
No insider sales of VRTX were filed in the last 90 days. 97 sales are on record for this company.
Where can I see VRTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects VRTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Grunsven Jasper van view on EDGAR
- - Kristen Ambrose view on EDGAR
- - Bruce I. Sachs view on EDGAR
- - Ourania Tatsis view on EDGAR
- - Amit Sachdev view on EDGAR
- - Bruce I. Sachs view on EDGAR
- - Alan M. Garber view on EDGAR
- - Ourania Tatsis view on EDGAR
- - Duncan McKechnie view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where VRTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow VRTX with a 7-day demo
- VRTX on your watchlist
- Every VRTX Form 4 filing on record
- Up to 3 months of VRTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
